

HR 2087

Drug Price Transparency Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 4, 2019

Current Status: Subcommittee Hearings Held.

Latest Action: Subcommittee Hearings Held. (May 21, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/2087>

Sponsor

Name: Rep. Doggett, Lloyd [D-TX-35]

Party: Democratic • **State:** TX • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Buchanan, Vern [R-FL-16]	R · FL		Apr 4, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Hearings By (subcommittee)	May 21, 2019
Ways and Means Committee	House	Referred to	Apr 4, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 2113	Related bill	Dec 24, 2020: Placed on the Union Calendar, Calendar No. 571.
116 HR 1570	Related bill	Dec 10, 2020: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 HR 19	Related bill	Dec 19, 2019: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
116 S 3129	Related bill	Dec 19, 2019: Read twice and referred to the Committee on Finance.
116 HR 2296	Related bill	Sep 24, 2019: Placed on the Union Calendar, Calendar No. 170.
116 S 2051	Related bill	Jun 28, 2019: Read twice and referred to the Committee on Finance.

Drug Price Transparency Act

This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

Actions Timeline

- **May 21, 2019:** Subcommittee Hearings Held.
- **Apr 5, 2019:** Referred to the Subcommittee on Health.
- **Apr 4, 2019:** Introduced in House
- **Apr 4, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Apr 4, 2019:** Referred to the Subcommittee on Health.